| 產品編號 | bs-5326R |
| 英文名稱 | Phospho-FGFR1+FGFR2 (Tyr463/Tyr466) Rabbit pAb |
| 中文名稱 | 磷酸化堿性成纖維細胞生長因子受體1/2（CD331/CD332）抗體 |
| 別 名 | FGFR1+FGFR2(phospho Tyr463/Tyr466); FGFR1+FGFR2(phospho Tyr463+Tyr466); FGFR2(phospho Y463+Y466); bFGF R; BFGFR; C FGR; CD 331; CD331; CD331 antigen; CEK; FGFBR; FGFR 1; Fibroblast growth factor receptor 1; FLG; FLG protein; FLJ14326; FLT 2; FLT2; Fms lik |
 |
Specific References (3) | bs-5326R has been referenced in 3 publications.
[IF=3.221] Zuyao Chen. et al. Intracellular FGF1 promotes invasion and migration in thyroid carcinoma via HMGA1 independent of FGF receptors. ENDOCR CONNECT. 2023 Mar;-1(aop): WB ; Human.
[IF=2.886] Yang Q et al. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade. Cancer Manag Res
. 2020 Jun 24;12:4937-4948. WB ; Mouse.
[IF=1.837] Yang Zhang. et al. Plumbagin Inhibits Proliferation, Migration, and Invasion of Retinal Pigment Epithelial Cells Induced by FGF-2. Tissue Cell. 2021 Oct;72:101547 WB ; Human.
|
| 產品類型 | 磷酸化抗體 |
| 研究領域 | 腫瘤 免疫學 生長因子和激素 轉錄調節(jié)因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Mouse,Rat (predicted: Rabbit,Pig,Cow,Chicken,Horse) |
| 產品應用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 88 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 細胞漿 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human FGFR1 around the phosphorylation site of Tyr463: SE(p-Y)EL <Cytoplasmic> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through the cellular surface tyrosine kinase receptors. There are four members of the FGF receptor family: FGFR-1 (flg), FGFR-2 (bek, KGFR), FGFR-3 and FGFR-4. Each receptor contains an extracellular ligand binding domain, a transmembrane region and a cytoplasmic kinase domain (1). Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues (2). Seven tyrosine residues in the cytoplasmic tail of FGFR-1 can be phosphorylated: Tyr463, Tyr583, Tyr585, Tyr653, Tyr654, Tyr730 and Tyr766. Tyrosine 653 and 654 are important for catalytic activity of the activated FGFR and are essential for signaling (3). The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCgamma. Function: Receptor for fibroblast growth factors FGF2 and FGF1. Receptor for FGF23 in the presence of KL (By similarity). Promotes mitogenesis in response to fibroblast growth factors. Activates PLCG1. Subunit: Homodimer. Interacts with KLB. Interacts with KL and FGF23. Interacts with SHB and GRB10. Interacts with PLCG1 (via SH2 domains). Interacts with KAL1; this interaction does not interfere with FGF2-binding to FGFR1, but prevents binding of heparin-bound FGF2. Interacts with SOX2 and SOX3. Subcellular Location: Membrane; Single-pass type I membrane protein. Tissue Specificity: Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells. Post-translational modifications: Binding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor. DISEASE: Defects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily. Contains 3 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain. SWISS: P11362 Gene ID: 2260 Database links: Entrez Gene: 2260 Human Entrez Gene: 14182 Mouse Omim: 136350 Human SwissProt: P11362 Human SwissProt: P16092 Mouse Unigene: 264887 Human Unigene: 265716 Mouse Unigene: 207203 Rat Unigene: 9797 Rat 堿性成纖維細胞生長因子(bFGF)是一種多功能的生長因子,具有促進細胞有絲分裂和誘導新血管形成作用,和其受體(FGFR1)堿性成纖維細胞生長因子受體結合之后,在人體各組織中具有廣泛的生物學活性和生理病理作用.越來越多的研究表明腫瘤細胞中bFGF-R1過度表達對腫瘤發(fā)生發(fā)展具有重要意義。 |
| 產品圖片 |
Sample:
U87MG(Human) Cell Lysate at 30 ug
Primary: Anti-Phospho-FGFR1+FGFR2 (Tyr463/Tyr466) (bs-5326R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 88 kD
Observed band size: 73 kD
Paraformaldehyde-fixed, paraffin embedded (mouse kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Phospho-FGFR1+FGFR2 (Tyr463/Tyr466)) Polyclonal Antibody, Unconjugated (bs-5326R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (rat kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Phospho-FGFR1+FGFR2 (Tyr463/Tyr466)) Polyclonal Antibody, Unconjugated (bs-5326R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human laryngeal carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Phospho-FGFR1+FGFR2 (Tyr463/Tyr466)) Polyclonal Antibody, Unconjugated (bs-5326R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Phospho-FGFR1+FGFR2 (Tyr463 Tyr466)) Polyclonal Antibody, Unconjugated (bs-5326R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Human glioma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Phospho-FGFR1+FGFR2 (Tyr463 Tyr466)) Polyclonal Antibody, Unconjugated (bs-5326R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Antigen:
1.phosphopeptide(blue),0.2ug/100ul;
2.non-phosphopeptide(red),0.2ug/100ul;
Primary:Antibody,1:200,1:400,1:800,1:1600,1:3200,1:6400,1:12800;
Secondary:HRP conjugated Goat Anti-Rabbit igG(Bbs-0295G-HRP)at1:5000;
TMB(C-0024)staining:
Read the data in Microplate Reader by 450nm
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
